mRNA 疫苗市场－全球产业规模、份额、趋势、机会和预测，按 mRNA 类型、应用、地区和竞争细分，2020-2030 年

2024年，全球mRNA疫苗市值为114.5亿美元，预计2030年将达到183.7亿美元，预测期内复合年增长率为8.34%。受新冠疫苗成功及该技术潜力不断扩大的推动，全球mRNA疫苗市场经历了快速成长。例如，根据世界卫生组织的数据，心血管疾病（CVD）是世界主要死因，每年约夺走1,790万人的生命。心血管疾病包括心臟和血管疾病，大多数死亡是由心臟病发作和中风引起的，通常影响70岁以下的人。

mRNA疫苗使用合成的信使RNA来引导细胞产生触发免疫反应的蛋白质。与传统疫苗平台相比，这种方法可以加快开发和生产速度。市场不再局限于传染病，因为正在进行的研究正在探索mRNA在癌症免疫治疗、遗传性疾病和自体免疫疾病的应用。脂质奈米颗粒递送系统的进步提高了mRNA疫苗的稳定性和效率，为治疗创新开闢了新的机会。各公司正大力投资扩展mRNA研究管道和生产基础设施，以满足长期需求。监管机构也不断调整，以适应mRNA技术的快速发展。大众对mRNA疫苗的认知度和接受度的提高，进一步推动了其在不同地区的应用。儘管冷链物流和高生产成本等挑战依然存在，但随着新进业者和策略合作的推进，市场仍在不断发展。随着技术的成熟，mRNA疫苗有望成为现代预防和治疗医学的基石，提供有针对性、个人化和可扩展的医疗保健解决方案。

关键市场驱动因素

快速疫苗研发需求不断成长

主要市场挑战

冷炼和储存要求

主要市场趋势

疫苗以外的治疗领域多元化发展

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：临床试验分析

第五章：顾客之声

第六章：全球mRNA疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依 mRNA 类型（核苷修饰 mRNA、未修饰 mRNA、自扩增 mRNA）
  • 依应用（COVID-19 mRNA 疫苗、非 COVID-19 mRNA 疫苗、其他）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司 (20242)
• 产品市场图
  • 依 mRNA 类型
  • 按应用
  • 按地区

第七章：北美mRNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第八章：欧洲mRNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太地区mRNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第十章：南美mRNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲 mRNA 疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 驱动程式
• 挑战

第十三章：市场趋势与发展

• 最新动态
• 併购
• 产品发布

第 14 章：全球 mRNA 疫苗市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Arcturus Therapeutics Holdings Inc.
• BioNTech SE
• CureVac NV
• Daiichi Sankyo Company Limited.
• Ethris GmbH
• GlaxoSmithKline plc
• Gennova Biopharmaceuticals Ltd
• Moderna, Inc.
• Pantherna Therapeutics GmbH
• Providence Therapeutics

第 17 章：策略建议

第18章调查会社について・免责事项

Global mRNA Vaccine Market was valued at USD 11.45 billion in 2024 and is expected to reach USD 18.37 Billion by 2030 with a CAGR of 8.34% during the forecast period. The global mRNA Vaccine market has experienced rapid growth driven by the success of COVID-19 vaccines and the expanding potential of the technology. For instance, according to WHO, cardiovascular diseases (CVDs) are the world's leading cause of death, claiming around 17.9 million lives annually. They include heart and blood vessel disorders, with most deaths caused by heart attacks and strokes, often affecting people under 70.

mRNA Vaccines use a synthetic version of messenger RNA to instruct cells to produce proteins that trigger an immune response. This method enables faster development and manufacturing compared to traditional vaccine platforms. The market is no longer limited to infectious diseases, as ongoing research explores mRNA's application in cancer immunotherapy, genetic disorders, and autoimmune conditions. Advancements in lipid nanoparticle delivery systems have improved the stability and efficiency of mRNA Vaccines, opening new opportunities for therapeutic innovation. Companies are investing heavily in expanding mRNA research pipelines and manufacturing infrastructure to support long-term demand. Regulatory agencies are also adapting to accommodate the rapid pace of development associated with mRNA technologies. The rise in public awareness and acceptance of mRNA Vaccines has further boosted adoption across various geographies. While challenges such as cold chain logistics and high production costs remain, the market continues to evolve with new entrants and strategic collaborations. As technology matures, mRNA Vaccines are expected to become a cornerstone of modern preventive and therapeutic medicine, offering targeted, personalized, and scalable healthcare solutions.

Key Market Drivers

Rising Demand for Rapid Vaccine Development

The rising demand for rapid vaccine development is a major force driving the global mRNA Vaccine market. For instance, on 29 July 2024, Bio-Manguinhos/Fiocruz, one of Latin America's largest vaccine manufacturers, joined CEPI's Global South network. This partnership aims to enhance rapid and equitable vaccine responses to emerging infectious diseases by expanding manufacturing capacity across the Latin American and Caribbean region, strengthening preparedness for future epidemic and pandemic threats through localized production and regional collaboration. Traditional vaccine development can take years, involving complex cultivation, inactivation, or protein purification processes. In contrast, mRNA Vaccines can be designed and produced within weeks once a target pathogen's genetic sequence is known. This speed has become crucial in responding to public health emergencies, as demonstrated during the COVID-19 pandemic. Governments, healthcare organizations, and pharmaceutical companies now recognize the importance of having platforms that allow for quick vaccine adaptation and deployment. mRNA technology offers a flexible and programmable approach. By simply changing the mRNA sequence, developers can target new variants or different diseases without overhauling the entire production process. This flexibility allows for rapid response not only to pandemics but also to emerging infectious threats and seasonal outbreaks. The global health landscape is increasingly shaped by unpredictable disease patterns, making rapid vaccine development a strategic priority.

The ability to accelerate vaccine research and approval timelines also aligns with global efforts to strengthen pandemic preparedness. Investments are being directed toward expanding mRNA production infrastructure, streamlining regulatory pathways, and establishing stockpiles of platform technologies. As demand grows for adaptable and efficient vaccine solutions, mRNA platforms are emerging as essential tools in modern immunization strategies.

Key Market Challenges

Cold chain and storage requirements

Cold chain and storage requirements present a significant challenge to the growth and accessibility of the global mRNA Vaccine market. Unlike traditional vaccines that can often be stored at standard refrigeration temperatures, many first-generation mRNA Vaccines require ultra-cold storage conditions, sometimes as low as -70°C. These extreme requirements create logistical hurdles, especially in developing countries or remote regions where ultra-low temperature freezers and reliable electricity are limited or unavailable. Maintaining the cold chain from manufacturing facilities to administration sites demands specialized equipment, constant temperature monitoring, and trained personnel. Any break in this chain can compromise the integrity and efficacy of the vaccine, leading to waste and reduced immunization rates. This complexity increases distribution costs and slows down deployment, particularly during mass vaccination campaigns or emergency responses.

Efforts are being made to develop mRNA Vaccines that are more stable at higher temperatures, which would simplify storage and handling. Some newer formulations have achieved stability at standard refrigeration levels for limited durations, offering hope for wider accessibility. However, such innovations are still under development and not yet broadly available for all mRNA-based products. Until more thermostable solutions become mainstream, the cold chain will remain a critical limiting factor. Addressing this issue is essential for expanding the reach of mRNA Vaccines globally, especially in regions with fragile healthcare infrastructure.

Key Market Trends

Diversification Into Therapeutics Beyond Vaccines

Diversification into therapeutics beyond vaccines is transforming the landscape of the global mRNA Vaccine market. While initial breakthroughs centered on infectious diseases like COVID-19, mRNA technology is now being harnessed for a broad spectrum of therapeutic applications. Oncology is a primary focus, where personalized cancer vaccines use patient-specific tumor mutations to train the immune system to target malignant cells. Companies like BioNTech and Moderna are actively developing clinical programs aimed at various cancers, including melanoma, lung, and pancreatic types.

The appeal of mRNA in oncology lies in its adaptability and speed. Developers can rapidly design and produce vaccines that match an individual's cancer profile, offering a level of customization that traditional therapies cannot provide. This approach not only enhances treatment precision but also opens the door to more effective combination therapies with checkpoint inhibitors or immunomodulators. In genetic disorders, mRNA therapies are being explored as a way to replace faulty or missing proteins. Diseases such as cystic fibrosis or certain metabolic conditions are potential targets, where mRNA could provide temporary yet repeated protein correction. This method offers a less invasive and potentially safer alternative to gene editing technologies. Autoimmune diseases are also emerging as a new frontier. mRNA may help retrain the immune system to tolerate self-antigens, offering novel treatments for conditions like multiple sclerosis or type 1 diabetes. This shift toward broader therapeutic use signals a long-term evolution of the mRNA platform beyond its vaccine origins.

Key Market Players

• Arcturus Therapeutics Holdings Inc.
• BioNTech SE
• CureVac N.V.
• Daiichi Sankyo Company Limited.
• Ethris GmbH
• GlaxoSmithKline plc
• Gennova Biopharmaceuticals Ltd
• Moderna, Inc.
• Pantherna Therapeutics GmbH
• Providence Therapeutics

Report Scope:

In this report, the Global MRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Vaccine Market, By mRNA Type:

• Nucleoside-modified mRNA
• Unmodified mRNA
• Self-Amplifying mRNA

mRNA Vaccine Market, By Application:

• COVID-19 mRNA Vaccines
• Non COVID-19 mRNA Vaccines
• Others

mRNA Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MRNA Vaccine Market.

Available Customizations:

Global MRNA Vaccine Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

• 4.1. Ongoing Clinical Trials
• 4.2. Completed Clinical Trials
• 4.3. Terminated Clinical Trials
• 4.4. Breakdown of Pipeline, By Development Phase
• 4.5. Breakdown of Pipeline, By Status
• 4.6. Breakdown of Pipeline, By Study Type
• 4.7. Breakdown of Pipeline, By Region
• 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global mRNA Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
  • 6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
  • 6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.4. By Company (20242)
• 6.3. Product Market Map
  • 6.3.1. By mRNA Type
  • 6.3.2. By Application
  • 6.3.3. By Region

7. North America mRNA Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
  • 7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States mRNA Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By mRNA Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Canada mRNA Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By mRNA Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Mexico mRNA Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By mRNA Type
      • 7.3.3.2.2. By Application

8. Europe mRNA Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
  • 8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France mRNA Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By mRNA Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Germany mRNA Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By mRNA Type
      • 8.3.2.2.2. By Application
  • 8.3.3. United Kingdom mRNA Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By mRNA Type
      • 8.3.3.2.2. By Application
  • 8.3.4. Italy mRNA Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By mRNA Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Spain mRNA Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By mRNA Type
      • 8.3.5.2.2. By Application

9. Asia-Pacific mRNA Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
  • 9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
  • 9.2.3. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China mRNA Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By mRNA Type
      • 9.3.1.2.2. By Application
  • 9.3.2. India mRNA Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By mRNA Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Japan mRNA Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By mRNA Type
      • 9.3.3.2.2. By Application
  • 9.3.4. South Korea mRNA Vaccine Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By mRNA Type
      • 9.3.4.2.2. By Application
  • 9.3.5. Australia mRNA Vaccine Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By mRNA Type
      • 9.3.5.2.2. By Application

10. South America mRNA Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
  • 10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil mRNA Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By mRNA Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Argentina mRNA Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By mRNA Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Colombia mRNA Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By mRNA Type
      • 10.3.3.2.2. By Application

11. Middle East and Africa mRNA Vaccine Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
  • 11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
  • 11.2.3. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa mRNA Vaccine Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By mRNA Type
      • 11.3.1.2.2. By Application
  • 11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By mRNA Type
      • 11.3.2.2.2. By Application
  • 11.3.3. UAE mRNA Vaccine Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By mRNA Type
      • 11.3.3.2.2. By Application

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Merger Acquisition
• 13.3. Product launches

14. Global mRNA Vaccine Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Arcturus Therapeutics Holdings Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Product Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. BioNTech SE
• 16.3. CureVac N.V.
• 16.4. Daiichi Sankyo Company Limited.
• 16.5. Ethris GmbH
• 16.6. GlaxoSmithKline plc
• 16.7. Gennova Biopharmaceuticals Ltd
• 16.8. Moderna, Inc.
• 16.9. Pantherna Therapeutics GmbH
• 16.10. Providence Therapeutics

17. Strategic Recommendations

18. About Us & Disclaimer